Halozyme to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 27, 2023 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences.
Related news for (HALO)
- Halozyme Therapeutics Added to Russell 1000® Index
- Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
- Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Halozyme to Host Investor Business Forum and Long-Term Outlook Call